{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:04:26Z","timestamp":1761919466415},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2011,6,10]],"date-time":"2011-06-10T00:00:00Z","timestamp":1307664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00115-011-3319-2","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T18:42:39Z","timestamp":1307558559000},"page":"1314-1319","source":"Crossref","is-referenced-by-count":11,"title":["Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab"],"prefix":"10.1007","volume":"82","author":[{"given":"C.","family":"Warnke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.P.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.C.","family":"Kieseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,10]]},"reference":[{"key":"3319_CR1","doi-asserted-by":"crossref","unstructured":"Warnke C, Adams O, Gold R et al (2011) Progressive multifokale Leukoenzephalopathie unter Natalizumab: Erste M\u00f6glichkeiten einer Risikostratifizierung? Nervenarzt (Epub ahead of print)","DOI":"10.1007\/s00115-010-3091-8"},{"key":"3319_CR2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295\u2013303","journal-title":"Ann Neurol"},{"key":"3319_CR3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","volume":"68","author":"West","year":"2010","unstructured":"West TW, Cree BA (2010) Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68:395\u2013399.","journal-title":"Ann Neurol"},{"key":"3319_CR4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1352458510389103","volume":"17","author":"Kaufman","year":"2011","unstructured":"Kaufman MD, Lee R, Norton H (2011) Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler 17(4):490\u2013494","journal-title":"Mult Scler"},{"key":"3319_CR5","unstructured":"Sandrock A, Hotermans C, Richman S et al (2011) Risk Stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Neurology 76(Suppl 4) P03.248"},{"key":"3319_CR6","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/gut.2007.145698","volume":"57","author":"Verbeeck","year":"2008","unstructured":"Verbeeck J, Van Assche G, Ryding J et al (2008) JC viral loads in patients with Crohn\u2019s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57:1393\u20131397","journal-title":"Gut"},{"key":"3319_CR7","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1099\/vir.0.18842-0","volume":"84","author":"Stolt","year":"2003","unstructured":"Stolt A, Sasnauskas K, Koskela P et al (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84:1499\u20131504","journal-title":"J Gen Virol"},{"key":"3319_CR8","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","volume":"5","author":"Kean","year":"2009","unstructured":"Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363","journal-title":"PLoS Pathog"},{"key":"3319_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","volume":"199","author":"Egli","year":"2009","unstructured":"Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837\u2013846","journal-title":"J Infect Dis"},{"key":"3319_CR10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","volume":"71","author":"Knowles","year":"2003","unstructured":"Knowles WA, Pipkin P, Andrews N, et al (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115\u2013123","journal-title":"J Med Virol"},{"key":"3319_CR11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jmv.21710","volume":"82","author":"Matos","year":"2010","unstructured":"Matos A, Duque V, Beato S et al (2010) Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 82:494\u2013504","journal-title":"J Med Virol"},{"key":"3319_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","volume":"68","author":"Goelz","year":"2010","unstructured":"Goelz SE, Gorelik L, Subramanyam M (2010) Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann Neurol 68(3):304\u2013310","journal-title":"Ann Neurol"},{"key":"3319_CR13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415","journal-title":"N Engl J Med"},{"key":"3319_CR14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387\u2013401","journal-title":"N Engl J Med"},{"key":"3319_CR15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00115-010-3075-8","volume":"82","author":"Aktas","year":"2011","unstructured":"Aktas O, Ingwersen J, Kieseier BC et al (2011) Orales Fingolimod bei Multipler Sklerose. Therapeutische Modulation des Sphingosin-1-Phosphat-Systems. Nervenarzt 82:215\u2013225","journal-title":"Nervenarzt"},{"key":"3319_CR16","unstructured":"www.whocc.no\/atc_ddd_index\/?code=L04AA"},{"key":"3319_CR17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/WNL.0b013e31820db341","volume":"76","author":"Mehling","year":"2011","unstructured":"Mehling M, Johnson TA, Antel J et al (2011) Clinical immunology of the sphingosine 1-phsophate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76(Suppl 3):20\u201327","journal-title":"Neurology"},{"key":"3319_CR18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","volume":"76","author":"Kowarik","year":"2011","unstructured":"Kowarik MC, Pellkofer HL, Cepok S et al (2011) Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 76:1214\u20131221","journal-title":"Neurology"},{"key":"3319_CR19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus- clinical features and pathogenesis. Lancet Neurol 9:425\u2013437","journal-title":"Lancet Neurol"},{"key":"3319_CR20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","volume":"67","author":"Warnke","year":"2010","unstructured":"Warnke C, Menge T, Hartung HP et al (2010) Natalizumab and progressive multifocal leukoencephalopathy what are the causal factors and can it be avoided? Arch Neurol 67:923\u2013930","journal-title":"Arch Neurol"},{"key":"3319_CR21","doi-asserted-by":"crossref","unstructured":"Haghikia A, Perrech M, Pula B et al (2011) Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One (in press)","DOI":"10.1371\/journal.pone.0018506"},{"key":"3319_CR22","doi-asserted-by":"crossref","unstructured":"O\u2019Connor PW, Goodman A, Kappos L et al (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (Epub ahead of print)","DOI":"10.1212\/WNL.0b013e31821e7c8a"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-011-3319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-011-3319-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-011-3319-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T14:32:31Z","timestamp":1560263551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-011-3319-2"}},"subtitle":["Empfehlungen zur JC-Virus-Serologie"],"short-title":[],"issued":{"date-parts":[[2011,6,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["3319"],"URL":"https:\/\/doi.org\/10.1007\/s00115-011-3319-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,10]]}}}